ArticleFrontiers in medicine2025
Frequency-reduction strategy of roxadustat in patients undergoing peritoneal dialysis: a multi-center retrospective cohort study.
Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Although dose reduction is the guideline-recommended tapering strategy for roxadustat to maintain target hemoglobin levels in peritoneal dialysis (PD) patients during the maintenance phase, reducing the administration frequency represents another potential clinical approach. However, the specific efficacy of this strategy in sustaining target hemoglobin levels remains unclear. Methods: This was a retrospective cohort study conducted from 1 January 2021 to 31 December 2024, enrolling PD patients from three dialysis centers in South China. Participants who achieved target hemoglobin levels were stratified into two groups based on roxadustat tapering strategies: The dose-reduction group, in which the per-dose amount was gradually decreased while maintaining the administration frequency, and the frequency-reduction group, in which the administration frequency was reduced without changing the per-dose amount. During a 12-month follow-up period, with assessments conducted every 3 months, mean hemoglobin levels, hemoglobin target attainment rates, and hemoglobin variability-evaluated using the residual standard deviation (RSD) method-were compared between the two tapering strategies. The association between hemoglobin target non-attainment and tapering strategies was analyzed using Cox proportional hazards models. Results: Among the 402 PD patients included in the analysis, the mean age was 45.3 ± 13.8 years and 55.5% were male. No significant difference was observed in the hemoglobin change trend and mean hemoglobin levels between the two groups throughout the follow-up period. Compared to the dose-reduction group, the patients who reduced dosing frequency demonstrated significantly higher hemoglobin target attainment rates at months 3 (64.1% vs. 40.4%), 6 (55.6% vs. 43.2%), and 12 (49.2% vs. 36.6%; all Conclusion: Compared to the dose-reduction group, the frequency-reduction group showed higher hemoglobin target attainment rates, lower hemoglobin variability, and a reduced risk of hemoglobin target non-attainment. The frequency-reduction strategy appears to be a potential tapering approach for peritoneal dialysis (PD) patients.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.